Filing Flows › Regen BioPharma (RGBP) › Q2 FY25
Regen BioPharma (RGBP) Q2 FY25 earnings results (second quarter fiscal 2025)
10-Q filed May 28, 2025
Regen BioPharma (RGBP) reported revenue of $59K for the second quarter fiscal 2025 (Q2 FY25), 0% from a year earlier and 0% from the quarter before. Operating margin was -191.9%, net loss $19K (32.8% of revenue).
Regen BioPharma, Q2 FY25: revenue $59K (0% year over year), operating margin -191.9%, net loss $19K, operating cash flow −$101K. The chart follows the revenue to costs, profit and cash.
| Q2 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $59K | 0% | 0% |
| Operating profit | −$113K | — | — |
| Net earnings | −$19K | — | — |
| Operating cash flow | −$101K | — | — |
What changed
Revenue was $59K in Q2 FY25, roughly flat year over year and roughly flat from the previous quarter.
Operating costs exceeded revenue by $113K, an operating margin of -191.9%. Total costs grew 8% against flat revenue. The fastest-growing cost line was Other operating costs (+44%). The quarter ended with a net loss of $19K, narrower than the previous quarter's $515K loss. Non-operating items added $94K, -486% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$101K. Working capital and other items used $82K.
Questions
What was Regen BioPharma's revenue in the second quarter fiscal 2025?
Regen BioPharma (RGBP) reported revenue of $59K for the second quarter fiscal 2025 (Q2 FY25), 0% from a year earlier and 0% from the quarter before.
Was Regen BioPharma profitable in the second quarter fiscal 2025?
Operating loss was $113K (-191.9% of revenue) and net loss $19K.
Source: Regen BioPharma 10-Q on SEC EDGAR.